Organization | Institut Sainte Catherine

Institut Sainte Catherine Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Avignon France (1946)

Organization Overview

First Clinical Trial

2005

NCT00268333

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Institut Sainte Catherine, 84082 Avignon, France | Institut Sainte Catherine - Avignon | Institut Ste Catherine-AVIGNON

Active Ingredients

Drugs in Phase 3 Trials (1)

clopidogrel (plavix) (1 trial)

Drugs in Phase 2 Trials (8)

bevacizumab (avastin) (1 trial)

cetuximab (erbitux) (2 trials)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (3 trials)

irinotecan (Camptosar) (1 trial)

leucovorin (2 trials)

oxaliplatin (eloxatin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Colorectal Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Pancreatic Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 9